Flagship Pioneering and Harbinger Health have appointed Ajit Singh, Ph.D. as CEO-Partner of Flagship and CEO of Harbinger Health. Singh, a diagnostics industry veteran and Harbinger board member since 2024, succeeds Stephen Hahn, M.D., who will transition to CEO Emeritus and Special Advisor while remaining on the board, according to the press release.
Singh, who previously held senior roles at Siemens, BioImagene (acquired by Roche), and Artiman Ventures, brings over three decades of expertise in diagnostics, oncology, and AI-driven health technologies. He is also an Adjunct Professor at Stanford University.
“On behalf of the Board of Directors, I extend our gratitude to Steve for his leadership through Harbinger’s foundational phase during which he, together with the team, established a differentiated and validated platform, charted a clear product development path, and forged pivotal partnerships with leading cancer research institutions,” said Doug Cole, M.D., Co-founder and Board Chair, Harbinger and General Partner at Flagship Pioneering. “Harbinger will undoubtedly continue to benefit from Steve’s guidance as a board member and active advisor to the leadership team.”
Harbinger Health is developing blood-based tests using ctDNA methylation patterns and AI to detect cancers at their earliest stages, aiming to make multi-cancer early detection a routine, low-cost reality.
Flagship Pioneering, the innovation firm behind Moderna and more than 100 scientific ventures, continues to support Harbinger’s mission to transform cancer screening and prevention.
